Department of Justice Awarded a Contract to MCKESSON CORPORATION for $500,000.00

Summary of Award

**Summary of Federal Contract Award: McKesson Corporation and the U.S. Government**

The recent federal award documented in the JSON data reflects a contractual relationship between the U.S. federal government and McKesson Corporation, a prominent player in the healthcare industry. The primary focus of the contract is on the provision of pharmaceuticals, indicating a strategic alignment between the government’s health-related needs and McKesson’s capabilities in pharmaceutical manufacturing and distribution.

**Contract Overview:** The awarded contract, identified by the unique award ID "CONT_AWD_15B51925F00000101_1540_36W79720D0001_3600," is categorized as a delivery order with a type "C" classification, signifying that it functions under a delivery order framework. The contract pertains strictly to the supply of pharmaceuticals, valued at $500,000. The contract's structure suggests that both base and exercised options are fully utilized, emphasizing the government's commitment to this contract's outlined requirements. The award date is recorded as April 10, 2025, with the period of performance scheduled between May 1, 2025, and May 31, 2025. This relatively short duration indicates a well-defined and possibly urgent need for the procurement of pharmaceutical products, which McKesson is contracted to fulfill. **Awarding and Funding Agencies:** The contract is funded and awarded by the Department of Justice, specifically through its sub-agency, the Federal Prison System/Bureau of Prisons, with the office location noted as FCC Pollock. This collaboration underscores the necessity of pharmaceuticals within facilities managed by the Bureau of Prisons, aligning with the mission to ensure the health and safety of individuals within their jurisdiction. Additionally, the contract operates under a larger, indefinite delivery/requirements framework supported by the Department of Veterans Affairs as the parent awarding agency, which lends further credence to the importance of pharmaceutical supplies across various governmental health capacities. **Recipient Details:** McKesson Corporation, the recipient of this contract, is a leading healthcare services provider headquartered in Irving, Texas. Known widely for its pharmaceutical distribution, logistics, and health IT solutions, McKesson is a corporation recognized for its extensive industry network and robust supply chain capabilities. The company's classification falls under a corporate entity that is not tax-exempt, aligns with special designations, and is categorized as a U.S.-owned business. This highlights McKesson’s role in not only the pharmaceutical domain but also its ethical engagement in supporting national interests. **Scope of Products and Services:** With a specific focus on pharmaceutical preparation manufacturing, this contract taps into McKesson's expertise in handling a variety of medical products. The product or service categorization under code "6505" reflects a commitment to deliver drugs and biologicals, which aligns with the extensive product offerings in McKesson's portfolio. The company's operations, as indicated by the NAICS code "325412," point to their substantial role in pharmaceutical and medicine manufacturing, suggesting that the contract's obligations are within their operational capacity. **Contractual and Transactional Dynamics:** This firm-fixed-price contract suggests stability and predictable fiscal planning both for the government and McKesson, with an understanding of costs and services outlined clearly from the onset. The nature of negotiations, as indicated by solicitation procedures described as a "Negotiated Proposal/Quote," highlights a bidding environment focused on full and open competition. While no specific transaction details are provided in the JSON, the contract does not involve any subawards, emphasizing McKesson’s central role in the fulfillment process. **Performance and Compliance:** Details about compliance, such as the lack of a requirement for a commercial item test program and evaluated preference, indicate a streamlined operational engagement focusing on commercial products and services. The domestic focus, as suggested by the U.S. business ownership and domestic sourcing attributes, augments national economic support while aligning with federal procurement standards. **Conclusion:** In summary, the contract between McKesson Corporation and the U.S. government represents a cogent partnership aimed at fulfilling a precise governmental requirement for pharmaceuticals. McKesson’s role as a key player in healthcare logistics and distribution places it suitably for such commitments. This award not only emphasizes the importance of timely pharmaceutical supplies within federal agencies but also illustrates the strategic partnerships formed to meet critical healthcare needs swiftly and efficiently. The alignment of resources, industry expertise, and shared objectives between McKesson and governmental bodies exemplifies cooperative efforts in addressing public health requirements, particularly within federal systems.